HOME >> BIOLOGY >> NEWS
Zengen, Inc. receives patent application approval for proprietary peptide technology

WOODLAND HILLS, Calif. (October 2, 2003) - Zengen, Inc. announced today that the United States Patent Office has approved a patent application for "A Lys-Pro-Val Dimer, Formulations and Applications," which covers novel peptide CZEN 002. This marks the first patent application approval for CZEN 002, with issuance of the patent expected by the end of the year. In addition, Zengen holds multiple patents and patents-pending worldwide on its peptide technologies.

"This development provides further validation of the efficacy of CZEN 002," said R. Steven Davidson, Ph.D., President and CEO of Zengen. "The approved patent application claims are directed to the novel peptide, which has the ability to control infection and/or inflammation associated with, among other disease states, urogenital conditions, including vaginitis."

Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Company's proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. Zengen's peptides have broad applications as anti-inflammatory and anti-infective prescription pharmaceuticals and are based on the larger melanocortin peptide, alpha-Melanocyte-Stimulating Hormone (a-MSH).

About CZEN 002

A synthetic octapeptide, CZEN 002 was developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). There is abundant evidence of the anti-inflammatory and anti-infective activity of CZEN 002 from both in vivo and in vitro research.

Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth and subsequent interference with cell metabolism, all of which give rise to a broad range of life-threatening diseases and disorders. In preclinical and clinical studies, CZEN 002 has been shown to directly kill pathologi
'"/>

Contact: Kumiko Hakushi
hakushik@ruderfinn.com
310-479-9929
Zengen
2-Oct-2003


Page: 1 2

Related biology news :

1. Zengen, Inc. announces novel approach to reduce organ rejection
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
5. Research on carbohydrate metabolism receives historical recognition
6. K-States National Agricultural Biosecurity Center receives $1.3 Million from Department of Defense
7. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
8. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
9. University of Pittsburgh receives $10 million grant for head and neck cancer
10. LSU Vet School receives $9.9 million for infectious disease research
11. UCSB professor and director receives two national awards

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... Algenist continues ... collagen-based formulation unlocking collagen like never before. , Collagen is the key structural ... to market with Liquid Collagen™, which include: , First ...
(Date:8/10/2017)... NC (PRWEB) , ... August 09, 2017 , ... Each ... Almost half never recover well enough to live an independent lifestyle and, even worse, ... , A new discovery by doctors at the University of California Davis Medical Center ...
(Date:8/10/2017)... ... August 10, 2017 , ... CNA ... outlet had initiated coverage on Next Group Holdings, Inc. and see's significant opportunity ... geared toward those that cannot engage in traditional banking services. According to industry ...
(Date:8/8/2017)... ... August 08, 2017 , ... Cynvenio Biosystems, Inc. ... announced the launch of its second generation PD-L1 expression test. The new blood ... highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer ...
Breaking Biology Technology:
Cached News: